Harpoon Therapeutics Inc (HARP) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access HARP Annual Cash Flow →
Observing cash flow movements over recent quarters helps explain how Harpoon Therapeutics Inc adapts cash usage as operating conditions change.
Quarterly Report, GAAP in USD millions
ITEM
(Sep 30 2023)
9 Months
(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Operating Activities
Income-12.08
Depreciation & amortization1.27
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges1.73
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.44
Share-based Compensation3.12
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Accrued Interest On Convertible Notes Payable-
Non Cash Lease Expense1.08
Increase Decrease In Contract With Customer Liability-33.25
Derivative Gain Loss On Derivative Net-10.97
Issuance Cost For Series A Preferred Stock-
Accretion Of Redemption Value Discount3.74
Net Amortization Of Discounts And Premiums On Marketable Securities-0.22
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-1.01
Increase (Decrease) in Accrued Liabilities-2.85
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.34
Other Working Capital0.04
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.70
Discontinued operations0.00
Net Cash flow from Operating Activities-50.99
Investing Activities
Capital Expenditures-0.09
Sale of Capital Items1.28
Proceeds from Sale and Maturity of Marketable Securities3.50
Payments to Acquire Marketable Securities-15.65
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-10.96
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.31
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock4.03
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Convertible Notes Net Of Issuance Costs-
Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options Net-
Payments Of Deferred Initial Public Offering Costs-
Proceeds From Issuance Of Common Stock In Connection With Employee Benefit Plans0.19
Proceeds From Issuance Of Series A Mandatorily Redeemable Preferred Stock23.70
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities27.61
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-49.80
Total Cash Flow-34.34
4 historic quarters locked

Sign in to unlock the full Harpoon Therapeutics Inc cash flow history.

About Harpoon Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-23-062125

Figures are derived from filed reports and may be restated. Historical data is subject to revision.